THE US Food and Drug
Administration has announced
class-wide safety labelling changes
and new postmarket study
requirements for all extendedrelease
and long-acting (ER/LA)
opioid analgesics.
The updated indication states
that the opioids are indicated for
the management of pain “severe
enough to require daily, aroundthe-
clock, long-term opioid
treatment and for which alternative
treatment options are inadequate”.
The FDA is also requiring a new
boxed warning on ER/LA opioids
cautioning about neonatal opioid
withdrawal syndrome if they are
used during pregnancy.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.